-
Product Insights
NewNet Present Value Model: Kintara Therapeutics Inc’s Rostaporfin
Empower your strategies with our Net Present Value Model: Kintara Therapeutics Inc's Rostaporfin report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Drugs In Development, 2023’, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2023’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rostaporfin in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rostaporfin in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rostaporfin in Metastatic Breast Cancer Drug Details: Rostaporfin (REM-001) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mitoxantrone Hydrochloride in Neuroblastoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mitoxantrone Hydrochloride in Neuroblastoma Drug Details: Mitoxantrone hydrochloride is a anthracenedione antibiotic with antineoplastic activity. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BBT-015 in Chemotherapy Induced Neutropenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BBT-015 in Chemotherapy Induced Neutropenia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BBT-015 in Chemotherapy Induced Neutropenia Drug Details: BBT-015 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dianhydrogalactitol in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dianhydrogalactitol in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dianhydrogalactitol in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Dianhydrogalactitol (VAL-083/Dag) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dianhydrogalactitol in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dianhydrogalactitol in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dianhydrogalactitol in Glioblastoma Multiforme (GBM) Drug Details: Dianhydrogalactitol (VAL-083/Dag) is under development...